Cetuximab in refractory skin cancer treatment

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 257-261

  Kalapurakal, Sini J ^a   Malone, James ^a   Robbins, K Thomas ^a   Buescher, Lucinda ^a   Godwin, John ^a   Rao, Krishna ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cetuximab; Non melanoma; Skin cancer

Indexed keywords

CETUXIMAB;

ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; NON MELANOMA SKIN CANCER; RASH; SQUAMOUS CELL CARCINOMA; UNITED STATES;

EID: 84875274970     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.3491     Document Type: Article

References (22)

1. Urba W, Washington C, Nadiminti H. Cancer of the Skin Chapter 87. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine; 18th ed. 2012.
2. [Internet] Geneva, Switzerland: World Health Organization. Too Much Fun in the Sun Dangerous; Press Release WHO/40; 3 August 1999. http://www.who.int/inf-pr-1999/en/pr99-40.html
3. Veness MJ. Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma. Australas Radiol 2005; 49(5):365-376.
4. Veness MJ, Porceddu S, Palme CE, Morgan GJ. Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck 2007; 29(7):621-631.
5. Porceddu S, Campbell B, Rischin D, Corry J, Weih L, Guerrieri M et al. Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004; 60(2):365-373.
6. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005; 41(2):107-127.
7. Segaert S, Van CE. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16(9):1425-1433.
8. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009; 115(6):1286-1299.
9. Koutcher LD, Wolden S, Lee N. Severe Radiation Dermatitis in Patients With Locally Advanced Head and Neck Cancer Treated With Concurrent Radiation and Cetuximab. Am J Clin Oncol 2009 Oct;32(5):472-6.
10. Lee SS, Chu PY. Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer. Am J Otolaryngol 2010; 31(4):288-290.
11. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version1.1). Eur J Cancer. 2009 Jan;45(2):228-47.
12. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, Milano G. Pharmacological background of EGFR targeting. Ann Oncol 2004; 15(7):1007-1012.
13. Krahn G, Leiter U, Kaskel P, Udart M, Utikal J, Bezold G et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001; 37(2):251-259.
14. Booth DR. The hedgehog signalling pathway and its role in basal cell carcinoma. Cancer Metastasis Rev 1999; 18(2):261-284.
15. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008; 8(10):743-754.
16. Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010; 28(36):5321-5326.
17. Schnidar H, Eberl M, Klingler S, Mangelberger D, Kasper M, Hauser-Kronberger C et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res 2009; 69(4):1284-1292.
18. Mimeault M, Batra SK. Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev 2010; 62(3):497-524.
19. Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007; 143(7):889-892.
20. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN. Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 2008; 6(12):1066-1069.
21. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009; 219(1):80-83.
22. Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 2007; 18(7):827-829.